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Plasmacytoid DCs (pDCs) represent a special-
ized DC population that is capable of produc-
ing large amounts of type I IFNs (IFN- and 
IFN-) for antiviral immunity (Gilliet et al., 
2008).  Activation  of  pDCs  is  mediated  by 
toll-like receptors (TLRs) 7 and 9, intracellu-
lar receptors which recognize single-stranded 
RNA or unmethylated CpG DNA, respec-
tively (Hemmi et al., 2000; Jarrossay et al., 
2001; Diebold et al., 2004; Heil et al., 2004). 
Upon  binding  of  their  ligands,  both  TLR7 
and TLR9 recruit a cytoplasmic adaptor MyD88, 
downstream of which the signaling pathways 
are bifurcated to induce either inflammatory 
cytokines or type I IFNs (Akira et al., 2006). 
In pDCs, induction of type I IFNs critically 
depends  on  IFN  regulatory  factor  (IRF)  7 
(Honda et al., 2005b). IRF-7 makes a com-
plex with MyD88, TNF receptor–associated 
factor 6, and IL-1 receptor–associated kinases 
(IRAKs) and translocates to the nucleus upon 
phosphorylation (Kawai et al., 2004; Uematsu 
et al., 2005). Although recent evidence indi-
cates that IB kinase (IKK)  directly binds to 
and activates IRF-7 (Hoshino et al., 2006), 
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Plasmacytoid dendritic cells (pDCs) play a key role in antiviral immunity, but also contribute 
to the pathogenesis of certain autoimmune diseases, by producing large amounts of type I 
IFNs. Although activation of pDCs is triggered by engagement of nucleotide-sensing toll-
like receptors (TLR) 7 and 9, type I IFN induction additionally requires IB kinase (IKK)  
–dependent activation of IFN regulatory factor (IRF) 7. However, the signaling pathway 
mediating IKK- activation is poorly defined. We show that DOCK2, an atypical Rac activa-
tor, is essential for TLR7- and TLR9-mediated IFN- induction in pDCs. We found that the 
exposure of pDCs to nucleic acid ligands induces Rac activation through a TLR-independent 
and DOCK2-dependent mechanism. Although this Rac activation was dispensable for induc-
tion of inflammatory cytokines, phosphorylation of IKK- and nuclear translocation of  
IRF-7 were impaired in Dock2-deficient pDCs, resulting in selective loss of IFN- induction. 
Similar results were obtained when a dominant-negative Rac mutant was expressed in 
wild-type pDCs. Thus, the DOCK2–Rac signaling pathway acts in parallel with TLR engage-
ment to control IKK- activation for type I IFN induction. Owing to its hematopoietic  
cell-specific expression, DOCK2 may serve as a therapeutic target for type I IFN–related 
autoimmune diseases.
© 2010 Gotoh et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Although pDCs are normally generated in the BM in the 
absence of DOCK2, Dock2/ mice exhibit a severe reduc-
tion of pDCs in the spleen and lymph nodes (Gotoh et al., 
2008).  Therefore,  this  mislocalization  of  pDCs  may  have   
affected TLR7/9-mediated IFN- production in vivo. To 
determine more precisely the role of DOCK2 in type I IFN 
induction,  we  purified  pDCs  from  Flt3  ligand–induced   
BM-derived DCs and stimulated them in vitro with CpG-A, 
R848, and another TLR9 ligand CpG-B (1668; Krieg et al., 
1995). Although WT pDCs produced considerable amounts 
of IFN- and IFN- in response to these TLR ligands, 
TLR7/9-mediated type I IFN induction was severely impaired 
in Dock2/ pDCs (Fig. 1, B–D). Similar results were obtained 
when naive BM pDCs were stimulated with CpG-A (Fig. 1 E). 
In contrast, induction of IL-12p40 and IL-6 and up-regulation 
of costimulatory molecules occurred normally in Dock2/ 
pDCs (Fig. 1 F and not depicted). These results indicate that 
DOCK2 selectively controls type I IFN induction pathway 
during TLR7/9-mediated pDC activation.
Influenza A virus and HSV type 2 (HSV-2) are known to 
activate the TLR7 and TLR9 signaling pathways, respectively 
(Lund et al., 2003; Diebold et al., 2004). To examine whether 
DOCK2 is also important for virus-induced IFN- produc-
tion, WT and Dock2/ pDCs were stimulated with these   
viruses in vitro. Although WT pDCs produced large amounts 
of IFN- depending on a multiplicity of infection (MOI), 
production of IFN- by Dock2/ pDCs was markedly sup-
pressed at any MOIs tested (Fig. 1 G). Similar results were   
obtained when heat- or UV-inactivated virus and purified 
HSV-2 DNA were used (Fig. 1, H and I), indicating that 
DOCK2 controls IFN- induction independently of virus 
replication. In contrast, such a drastic difference was not found 
in IL-12p40 production, although Dock2/ pDCs produced 
less IL-12p40 than WT pDCs at a certain MOI (Fig. 1 G).
DOCK2 controls TLR7/9–mediated type I IFN induction  
via Rac activation
To explore the mechanism by which DOCK2 controls type I 
IFN induction, we first compared ligand uptake between 
WT and Dock2/ pDCs. The Cy5-labeled CpG-A was com-
parably incorporated into both types of pDCs (Fig. 2 A), 
indicating that DOCK2 deficiency does not affect CpG-A 
uptake. However, although WT pDCs exhibited a localized 
accumulation of F-actin in response to CpG-A, F-actin 
assembly was scarcely found in Dock2/ pDCs (Fig. 2 B).   
Because the morphological change was induced in WT pDCs 
treated with CpG-A–coated beads (Fig. 2 C), this actin   
polymerization,  as  previously  suggested  in  macrophages   
(Sanjuan et al., 2006), appeared to be triggered at the cell 
surface, independently of TLR9 engagement. Indeed, after 
CpG-A stimulation, Tlr9/ pDCs also exhibited polarized 
morphology with focused distribution of F-actin (Fig. 2 B). 
In human pDCs, it has been reported that CXCL16, a scav-
enger receptor, recognizes CpG-A at the cell surface and   
mediates its uptake (Gursel et al., 2006). However, CXCL16 
deficiency did not affect CpG-A uptake, actin polymerization, 
the signaling cascades leading to type I IFN induction are 
not completely defined. Elucidation of this regulatory mech-
anism would be clinically important because type I IFNs 
produced by pDCs have been implicated in the pathogen-
esis of autoimmune diseases such as psoriasis and systemic   
lupus erythematosus (Blanco et al., 2001; Nestle et al., 2005; 
Lande et al., 2007).
Rac is a member of the Rho family of GTPases that func-
tion as molecular “switches” by cycling GDP-bound inactive 
states and GTP-bound active states. Once activated, Rac   
interacts with multiple downstream effectors to regulate vari-
ous cellular functions including actin reorganization and gene 
expression. Stimulus-induced formation of the active GTP-
bound Rac is mediated by guanine nucleotide exchange 
factors (GEFs). DOCK2 is a member of the CDM family of 
proteins (Caenorhabditis elegans CED-5, mammals DOCK180, 
and Drosophila melanogaster myoblast city) and is predominantly 
expressed in hematopoietic cells (Reif and Cyster, 2002).   
Although DOCK2 does not contain the Dbl homology do-
main and the pleckstrin homology domain that are typically 
found in GEFs, DOCK2 catalyzes the GTP–GDP exchange 
reaction  for  Rac  via  its  Docker  (also  known  as  DHR-2)   
domain (Brugnera et al., 2002; Côté and Vuori, 2002). There 
is accumulating evidence that DOCK2 functions downstream 
of chemokine receptors and regulates migration of certain 
subsets of immune cells (Fukui et al., 2001; Nombela-Arrieta 
et al., 2004, 2007; Kunisaki et al., 2006; Shulman et al., 2006; 
Nishikimi et al., 2009). Indeed, pDCs, but not myeloid DCs, 
from Dock2-deficient (Dock2/) mice exhibit a severe defect 
in chemokine-induced Rac activation, resulting in reduction 
of motility and the loss of polarity during chemotaxis (Gotoh 
et al., 2008). Thus, DOCK2 is a major Rac GEF that controls 
migration of pDCs. However, the role of DOCK2 in TLR-
mediated pDC activation remains unknown.
In this paper, we present evidence that DOCK2 controls 
TLR7- and TLR9-mediated IFN- induction in pDCs via 
Rac activation. This Rac activation occurred independently 
of TLR engagement but was critically required for TLR- 
mediated IKK- activation and type I IFN induction. Our 
results thus define a novel regulatory mechanism controlling 
type I IFN induction in pDCs.
RESULTS AND DISCUSSION
DOCK2 is required for TLR7/9-mediated type I IFN 
induction in pDCs
To examine the role of DOCK2 in TLR-mediated cytokine 
production, we first measured serum IFN- and IL-12p40   
after intravenously injecting TLR ligands into WT and 
Dock2/ mice. When A-type CpG DNA (D19), a TLR9 
ligand (Verthelyi et al., 2001), was administrated, both WT 
and Dock2/ mice comparably produced IL-12p40 (Fig. 1 A). 
Similar results were obtained with a TLR7 ligand R848 
(Fig. 1 A; Hemmi et al., 2002), indicating that DOCK2 defi-
ciency does not affect TLR7/9-mediated inflammatory cyto-
kine production. Surprisingly, however, both CpG-A and R848 
failed to induce IFN- production in Dock2/ mice (Fig. 1 A).JEM VOL. 207, April 12, 2010  723
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kinetics as in WT pDCs (Fig. 2 D). However, CpG-A– 
induced  Rac  activation  was  almost  totally  abolished  in 
Dock2/ pDCs (Fig. 2 D). This defect in Rac activation 
was also observed when Dock2/ pDCs were stimulated 
with other TLR ligands such as R848, influenza A virus, 
HSV-2, and purified HSV-2 DNA (Fig. 2, E–G). In con-
trast, Rac activation and actin polymerization occurred nor-
mally in Dock2/ myeloid DCs stimulated with CpG-A 
(Fig. S2), indicating that the effect of DOCK2 deficiency on 
TLR  ligand–induced  Rac  activation  is  limited  to  pDCs.   
To directly examine whether Rac activation is involved in 
type I IFN induction in pDCs, we retrovirally transduced 
WT pDCs to express a dominant-negative Rac mutant   
and IFN- induction in mouse pDCs (Fig. S1, A–C). In   
addition, CpG-A uptake and actin polymerization were   
insensitive to pertussis toxin and the Src family kinase inhibi-
tor PP2 (Fig. S1, D and E), ruling out the possible involve-
ment  of  G  protein–coupled  receptors  and  tyrosine  kinase 
signaling pathways in these cellular functions, although treat-
ment with PP2, but not pertussis toxin, inhibited induction 
of both IFN- and IL-12p40 in WT pDCs (Fig. S1 F).
Having found that CpG-A induces actin polymeriza-
tion in TLR9-independent and DOCK2-dependent mech-
anisms, we compared Rac activation among WT, Tlr9/, 
and Dock2/ pDCs. In response to CpG-A, Rac was acti-
vated in Tlr9/ pDCs to the same extent and at the same 
Figure 1.  DOCK2 is required for TLR7/9-mediated type I IFN induction in pDCs. (A) Serum IFN- and IL-12p40 levels were compared between WT 
and Dock2/ mice after injection of CpG-A complexed with the cationic lipids DOTAP (left) or R848 (right). Data are the mean ± SD of three mice, and 
are representative of two independent experiments. **, P < 0.001. (B–I) The levels of IFN- (B, D, E, G, H, and I), IFN- (C and E), IL-12p40 (F, G, and I), and 
IL-6 (F) in cell culture supernatants were compared between WT and Dock2/ pDCs 24 h after stimulation with TLR7 or TLR9 ligands. Data are expressed as 
the mean ± SD of triplicate wells and are representative of three (B–G) or two (H and I) independent experiments. **, P < 0.001; *, P < 0.01. ND indicates 
below the detectable limit. (B, C, D, and F) Flt3 ligand–induced BM–derived pDCs (4 × 104 cells per well) were stimulated with CpG-A (B and C, 0–3 µM;  
F, 3 µM), CpG-B (B and C, 0–3 µM; F, 1 µM), or R848 (D and F, 100 nM). (E) Naive BM pDCs (4 × 104 cells per well) were stimulated with CpG-A (3 µM).  
(G) Flt3 ligand–induced BM-derived pDCs (2 × 105 cells per well) were infected with influenza A virus or HSV-2 at the indicated MOIs. (H) Flt3 ligand–
induced BM-derived pDCs (2 × 105 cells per well) were stimulated with live or inactivated influenza A virus or HSV-2 at an MOI of 0.5 or 0.3, respectively. 
(I) Flt3 ligand–induced BM-derived pDCs (4 × 105 cells per well) were stimulated with 2.74 µg/ml HSV-2 DNA.724 pDC IFN production requires DOCK2 | Gotoh et al.
ing IL-12p40 levels (Fig. 2 H). Similarly, the expression of 
T17N-Rac abrogated influenza A virus–mediated induction 
of IFN-, but not IL-12p40, in WT pDCs (Fig. 2 I). These 
(T17N-Rac). Compared with the cells expressing the WT 
Rac control, the expression of T17N-Rac markedly sup-
pressed CpG-A–induced IFN- production without affect-
Figure 2.  DOCK2 controls TLR7/9-mediated type I IFN induction in pDCs via Rac activation. (A) The uptake of CpG-A was compared between WT 
and Dock2/ pDCs after cells were incubated with 3 µM CpG-A–Cy5 at 37°C (filled area) or 4°C (open area) for 1 h. Before assay, cell surface fluores-
cence was quenched with 0.2% trypan blue. Representative profiles of three independent experiments are shown. (B and C) BM-derived pDCs from WT, 
Dock2/, and Tlr9/ mice were stimulated with 3 µM CpG-A for the indicated times (B) or CpG-A–coated polystyrene beads for 1 min (C). Cells were then 
fixed and stained with phalloidin. Representative images of two independent experiments are shown. DIC, differential interference contrast. Bars, 10 µm. 
(D–G) Activation of Rac was analyzed for BM-derived pDCs from WT (+/+), Dock2/, and Tlr9/ mice after stimulation with 3 µM CpG-A (D), 100 nM  
R848 (E), influenza A virus, or HSV-2 at a MOI of 0.5 (F) or 2.18 µg/ml HSV-2 DNA (G) for the indicated times. Data are representative of three (D and F)  
or two (E and G) independent experiments. (H and I) BM-derived WT pDCs were retrovirally transduced to express either T17N-Rac–IRES–GFP or WT Rac–
IRES–GFP. After fluorescence-activated cell sorting, GFP-positive cells (H, 4 × 104 cells per well; I, 6 × 104 cells per well) were stimulated with 3 µM CpG-A 
(H) or influenza A virus at an MOI of 0.5 (I) for 24 h. Data indicate the levels of IFN- and IL-12p40 in cell culture supernatants (mean ± SD of triplicate 
wells) and are representative of five (H) and two (I) independent experiments. **, P < 0.001; *, P < 0.01. ND indicates below the detectable limit.JEM VOL. 207, April 12, 2010  725
Brief Definitive Report
but not Dock2/, pDCs (Fig. 4 A). Recent evidence indi-
cates that PI3Ks (phosphatidylinositol-3 kinases) control the 
nuclear translocation of IRF-7 (Guiducci et al., 2008). How-
ever, phosphorylation of Akt, a downstream effector of 
PI3Ks, as well as that of ERK, JNK, and p38 occurred nor-
mally in Dock2/ pDCs stimulated with CpG-A (Fig. 4 B). 
Similarly,  DOCK2  deficiency  did  not  affect  CpG-A– 
induced degradation and autophosphorylation of IRAK-1, 
which is also essential for IRF-7 activation (Fig. 4, C and D; 
Uematsu et al., 2005).
IKK- is involved in phosphorylation and nuclear trans-
location of IRF-7 (Hoshino et al., 2006). IKK- carries two 
serine residues at positions 176 and 180 in the activation loop, 
which are phosphorylated during cellular stimulation (Häcker 
and Karin, 2006). In WT pDCs, IKK- was phosphorylated 
at these sites in response to CpG-A (Fig. 4 E). However, such 
phosphorylation  was  hardly  detected  in  both  Dock2/  
and Tlr9/ pDCs (Fig. 4, E and F). Moreover, IKK- 
phosphorylation was inhibited in WT pDCs by treating   
them with a cell-permeable dominant-negative Rac mutant   
(Tat–T17N-Rac; Fig. 4 G). A critical role of this IKK- 
phosphorylation in type I IFN induction was examined by 
luciferase  assays.  Overexpression  of  MyD88  augmented   
IRF-7–induced Ifna promoter activation (Fig. S4). This   
augmentation was inhibited by coexpression of an IKK- 
mutant encoding alanines instead of serines at positions 176 
and 180 (IKK- SSAA) as well as a kinase-inactive IKK- 
mutant (Fig. S4). Conversely, Ifna promoter activation was 
further enhanced by coexpression of an IKK- mutant with 
glutamates at these sites (IKK- SSEE), which mimics the   
effect of phosphorylated serines (Fig. S4). Collectively, these 
results  suggest  that  DOCK2-mediated  Rac  activation   
controls type I IFN induction, at least in part, through phos-
phorylation and activation of IKK-.
In this paper, we have provided evidence that DOCK2 
couples ligand stimulation to type I IFN induction in pDCs 
via Rac activation. We found that the exposure of pDCs to 
nucleic acid ligands induces Rac activation through a TLR-
independent and DOCK2-dependent mechanism. This Rac 
activation was not required for TLR engagement in early 
endosomes  and  IFN  signal–dependent  positive  feedback   
regulation. However, TLR-mediated IKK- activation was 
severely  impaired  in  pDCs  lacking  DOCK2  and  those   
expressing a dominant-negative Rac mutant, resulting in   
selective loss of type I IFN induction in these cells. Our   
results thus indicate that the DOCK2–Rac signaling path-
way acts in parallel with TLR engagement to control IKK-  
activation for type I IFN induction. Although the precise 
mechanism by which Rac controls IKK- activation is cur-
rently unknown, it has been reported that activation of IKK 
complex is regulated by a redox-dependent mechanism in 
other receptor systems (Oakley et al., 2009). As Rac is a 
cytosolic component of the NADPH (nicotinamide adenine 
dinucleotide phosphate) oxidase, Rac may therefore con-
trol IKK- activation through generation of reactive oxygen 
species. Alternatively, PAK (p21-activated kinase), a downstream 
results  indicate  that  DOCK2  controls  TLR7/9-mediated 
type I IFN induction in pDCs through Rac activation.
Type I IFN signaling and TLR engagement are unaffected  
in Dock2/ pDCs
Although activation of basally expressed IRF-7 induces type I 
IFN gene expression, robust type I IFN production requires 
IFN signal–dependent IRF-7 expression. This positive-feedback 
regulation involves a complex called IFN-stimulated gene 
factor 3, which is composed of STAT-1, STAT-2, and IRF-9 
(Honda et al., 2006). As CpG-A–mediated Irf7 induction was 
significantly reduced in Dock2/ pDCs at 3 h after stimula-
tion (Fig. 3 A), we examined whether DOCK2 functions 
downstream of type I IFN receptors. Although CpG-A–
induced STAT-1 phosphorylation was impaired in Dock2/ 
pDCs (Fig. 3 B), STAT-1 was normally phosphorylated in 
these cells in response to IFN- (Fig. 3 C). Consistent with 
this finding, the expression of Irf7 and Cxcl10, another IFN-
inducible gene, were comparably up-regulated in WT and 
Dock2/ pDCs after stimulation with IFN- (Fig. 3 D). 
These results suggest that DOCK2 controls the initial IFN 
induction pathway rather than the IFN signal–dependent 
positive-feedback loop.
Both TLR7 and TLR9 reside in the ER and are recruited 
to endolysosomes upon stimulation to detect internalized   
ligands (Latz et al., 2004; Leifer et al., 2004). As TLR9   
engagement by CpG-A in early endosomes is suggested to   
be important for robust type I IFN induction (Honda et al., 
2005a; Guiducci et al., 2006), we examined whether DOCK2 
deficiency alters subcellular localization of TLR9 and CpG-A. 
Although the majority of YFP-tagged TLR9 was localized in 
the ER under unstimulated conditions, this proportion was 
markedly reduced upon stimulation, irrespective of DOCK2 
expression (Fig. 3 E). More importantly, in WT and Dock2/ 
pDCs, TLR9-YFP and CpG-A–Cy5 comparably accumu-
lated  in  the  transferrin  receptor  (TfR)–positive  endosomal 
compartments at 1.5 and 6 h after stimulation (Fig. 3 F),   
indicating that DOCK2 deficiency does not interfere with 
TLR engagement in early endosomes. When LAMP-1– 
positive late endosomes/lysosomes were analyzed, the pro-
portion  of  TLR9  and  CpG-A  colocalized  with  LAMP-1 
somewhat decreased in Dock2/ pDCs at 6 h, compared 
with that in WT pDCs (Fig. 3 G). Although the precise mean-
ing of this difference remains unknown, it seems unlikely that 
this difference directly affects the ability of IFN- induction 
because such a difference was not found when WT and 
Dock2/ pDCs were stimulated with CpG-B (Fig. S3).
DOCK2-mediated Rac activation is critical for IKK- 
activation in pDCs
Having found that TLR engagement in early endosomes is 
unaffected in the absence of DOCK2, we next examined the 
nuclear translocation of IRF-7 by staining pDCs with anti–
IRF-7 antibody and DAPI. Although IRF-7 was expressed 
in the cytoplasm of unstimulated pDCs, stimulation with 
CpG-A induced nuclear accumulation of IRF-7 in WT, 726 pDC IFN production requires DOCK2 | Gotoh et al.
Although pDCs play a key role in antiviral immunity, 
there is growing evidence that pDCs also contribute to the 
pathogenesis  of  autoimmune  diseases  by  producing  large 
amounts of type I IFNs. Thus far, several molecules, includ-
ing IKK- and IRF-7, have been shown to control type I 
effector of Rac, may be directly or indirectly involved in 
IKK- activation, as was previously reported for other IKKs 
(Cammarano and Minden, 2001; Ehrhardt et al., 2004). Further 
studies will be required to determine how IKK- activation 
is controlled by Rac in pDCs.
Figure 3.  Type I IFN signaling and TLR engagement in early endosomes are unaffected in the absence of DOCK2. (A) Real-time PCR analysis of 
Irf7 and Ifna4 expression in BM-derived pDCs stimulated with 3 µM CpG-A for the indicated times. Data are expressed as the mean ± SD of triplicate 
reactions after normalization to expression of the gene encoding hypoxanthine guanine phosphoribosyl transferase 1 (Hprt1) and are representative of 
two independent experiments. **, P < 0.001; *, P < 0.01. (B and C) BM-derived WT and Dock2/ pDCs were stimulated with 3 µM CpG-A (B) or 500 U/ml 
IFN- (C) for the indicated times and analyzed for phosphorylation of STAT-1. Data are representative of three (B) and two (C) independent experiments. 
(D) Real-time PCR analysis of Irf7 and Cxcl10 expression in BM-derived pDCs stimulated with 500 U/ml IFN- for the indicated times. Data are expressed 
as the mean ± SD of triplicate reactions after normalization to Hprt1 expression and are representative of two independent experiments. (E–G) BM- 
derived pDCs retrovirally transduced with TLR9–YFP were stimulated with 3 µM CpG-A for the indicated times. After fixation, cells were stained with ER-
Tracker (E), anti–TfR antibody (F), or anti–LAMP-1 antibody (G). The area of TLR9-YFP or CpG-A–Cy5 merged with ER-Tracker (E), TfR (F), or LAMP-1  
(G) was calculated in each cell. Bars, 5 µm. (E) Data are expressed as the percentage of colocalization (mean ± SD; n = 10) and are representative of two 
independent experiments. (F and G) Data were pooled from three independent experiments and are expressed as the percentage of colocalization (mean ± 
SD) for 30 cells analyzed per group. **, P < 0.001.JEM VOL. 207, April 12, 2010  727
Brief Definitive Report
(Osaka University, Osaka, Japan) and S. Ueha and K. Matsushima (both from 
the  University  of  Tokyo,  Tokyo,  Japan),  respectively.  Age-matched  and   
sex-matched C57BL/6 mice were used as WT controls. Mice were kept   
under  specific  pathogen-free  conditions  in  the  animal  facility  of  Kyushu   
University. Animal protocols were approved by the committee of Ethics on 
Animal Experiment, Faculty of Medical Sciences, Kyushu University.
Reagents.  The  following  CpG  oligonucleotides  were  synthesized  at   
Hokkaido System Science: CpG-A (D19), ggTGCATCGATGCAgggggG; 
and CpG-B (1668), tccatgacgttcctgatgct (uppercase and lowercase letters in-
dicate  bases  with  phosphodiester-  and  phosphorothioate-modified  back-
bones, respectively). The Cy5-labeled CpG-A and CpG-B were obtained 
from Sigma-Aldrich. R848 was purchased from Enzo Life Sciences, Inc., 
and pertussis toxin and PP2 were obtained from EMD. For viral infection, 
HSV-2 (186 strain) and influenza A/New Caledonia/20/99 (H1N1) were used. 
IFN induction in pDCs. However, their ubiquitous expres-
sion precludes the use as therapeutic targets. Unlike these 
molecules, DOCK2 expression is limited to hematopoietic 
cells (Fukui et al., 2001). In addition, we have demonstrated 
in this paper that DOCK2 selectively controls type I IFN   
induction during TLR7/9-mediated pDC activation. There-
fore, DOCK2 may be a novel therapeutic target for control-
ling type I IFN–related autoimmune diseases.
MATERIALS AND METHODS
Mice. Dock2/, Tlr9/, and Cxcl16/ mice have been described elsewhere 
(Hemmi et al., 2000; Fukui et al., 2001; Shimaoka et al., 2007). Dock2/ 
mice were backcrossed with C57BL/6 mice for more than eight generations 
before use. Tlr9/ mice and Cxcl16/ BM cells were provided by S. Akira 
Figure 4.  DOCK2-mediated Rac activation is critical for IKK- activation in pDCs. (A) Subcellular localization of IRF-7 was compared between 
WT and Dock2/ pDCs after stimulation with CpG-A. DAPI was used to stain nuclei. Representative images of three independent experiments are shown. 
Bar, 5 µm. (B) BM-derived pDCs from WT and Dock2/ mice were stimulated with 3 µM CpG-A for the indicated times and analyzed for phosphorylation 
of Akt, ERK, JNK, or p38. Data are representative of at least two independent experiments. (C and D) BM-derived WT and Dock2/ pDCs were stimulated 
with 3 µM CpG-A for the indicated times and analyzed for the expression (C) and autophosphorylation (D) of IRAK-1. Data are representative of two in-
dependent experiments. (E–G) BM-derived pDCs from WT, Dock2/, and Tlr9/ mice were stimulated with 3 µM CpG-A for the indicated times and ana-
lyzed for serine phosphorylation of IKK- at positions 176 and 180. (G) Before stimulation, cells were treated with bacterially expressed GFP-tagged 
Tat–T17N-Rac or Tat–WT Rac (500 nM each) for 30 min at 37°C. Data are representative of three (E and G) or two (F) independent experiments.728 pDC IFN production requires DOCK2 | Gotoh et al.
ER-Tracker  Red  (Invitrogen).  The  DeltaVision  Restoration  Microscopy 
system (Applied Precision) with a 60× objective attached to a cooled charge-
coupled device camera was used for microscopy. Images were acquired with 
the DeltaVision SoftWorX Resolve 3D capture program and were collected 
as a stack of 0.2-µm increments. After deconvolution, images were viewed   
as a single section on the z axis. The area of TLR9 or CpG DNA (CpG-A 
or CpG-B) localized together with TfR, LAMP-1, or ER–Tracker was   
calculated  in  each  cell  using  the  MetaMorph  imaging  system  (Universal   
Imaging). The percentage of colocalization was determined by dividing the 
area of TLR9 or CpG DNA localized together with TfR, LAMP-1, or   
ER-Tracker by the total area of TLR9 or CpG DNA, respectively.
To examine the nuclear translocation of IRF-7, fixed cells were perme-
abilized for 5 min with 0.5% (wt/vol) saponin (Sigma-Aldrich). After being 
blocked with 20% goat serum for 30 min, cells were stained with anti–IRF-7 
antibody  (Invitrogen)  at  4°C  overnight  and  incubated  with  biotin- 
conjugated anti–rabbit IgG (Jackson ImmunoResearch Laboratories) fol-
lowed by Alexa Fluor 488–conjugated streptavidin (Molecular Probes). The 
cells were washed and mounted using fluorescent mounting medium (Dako) 
with DAPI (Wako Chemicals USA, Inc.). All images were taken with a laser-
scanning confocal microscope (LSM 510 META).
Real-time PCR. After treatment with RNase-free DNase I (Invitrogen), 
RNA samples were reverse transcribed with random primers (Invitrogen) 
and SuperScript III reverse transcriptase (Invitrogen). Quantitative real-time 
RT-PCR analysis was performed using specific primers (TaqMan Gene   
Expression Assays; Applied Biosystems).
Reporter assay. Reporter assay was performed as described elsewhere (Hoshino 
et al., 2006). In brief, 293T cells were seeded on a 24-well plate (7 × 104 cells 
per well). The next day, these cells were transfected with 56 ng of luciferase re-
porter plasmid alone or together with a combination of the expression plasmid 
for MyD88 (65.6 ng), IRF-7 (216.8 ng), or IKK- and its mutants (228 or 456 
ng). Cell lysates were prepared 24 h after transfection and luciferase activity was 
measured by the Dual-luciferase reporter assay system (Promega).
Statistical analysis. P-values were calculated using the two-tailed Student’s 
t test.
Online  supplemental  material. Fig. S1 shows the effect of CXCL16   
deficiency, pertussis toxin, or PP2 on CpG-A uptake, actin polymerization, 
and cytokine production in pDCs. Fig. S2 shows that DOCK2 deficiency 
does not affect CpG-A–induced actin polymerization and Rac activation in 
myeloid DCs. Fig. S3 shows that DOCK2 deficiency does not alter subcel-
lular localization of TLR9 and CpG-B in pDCs. Fig. S4 shows that the serine 
phosphorylation of IKK- at position 176/180 is critical for IRF-7– 
mediated type I IFN induction. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20091776/DC1.
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